Tall Cell Carcinoma with Reverse Polarity of Breast: Report of a Case with Unique Morphologic and Molecular Features

Mohamed JASSIM¹, Chennagiri S PREMALATA¹, Geeta V Patil OKALY ¹, Chunduri SRINIVAS²

Department of ¹Pathology and ²Surgical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, INDIA

ABSTRACT

Breast carcinomas are a heterogeneous group of malignancy, having variable clinical outcomes depending on their cellular and molecular properties. Tall cell carcinoma with reverse polarity (TCCRP) is a recently described rare entity, which shares morphological features with tall cell variant of papillary thyroid carcinoma but has a distinct morphological, immunohistochemical, and molecular profile. We describe a case of a 40-year-old female patient, who presented with lump in the breast. The patient underwent lumpectomy and was diagnosed as tall cell carcinoma with reverse polarity. Immunohistochemistry and bi-directional Sanger sequencing for IDH2 mutation were used for diagnosis. Tall cell carcinoma with reverse polarity is a rare and newly described entity with characteristic morphological and molecular findings, which carries an excellent prognosis.

Key Words: Breast carcinoma, Tall cell carcinoma, Reverse polarity, Solid papillary, IDH2

INTRODUCTION

Tall cell carcinoma with reverse polarity (TCCRP) is a rare type of invasive breast carcinoma with characteristic immuno-morphologic and molecular findings and is often difficult to diagnose. Eusebi et al., in 2003, reported a rare variety of breast carcinoma having features similar to papillary thyroid carcinoma described as “Breast tumor resembling the tall cell variant of papillary thyroid carcinoma” (1). These tumors were also called breast tumor resembling the tall cell variant of papillary thyroid carcinoma; solid papillary breast carcinoma resembling tall cell variant of papillary thyroid carcinoma; solid papillary carcinoma with reverse polarity (1–5). These tumors were consistently immuno-negative for TTF-1, thyroglobulin and HBME1, and there was no associated thyroid malignancy. Chiang et al. described 13 more cases and also identified the IDH2 hotspot mutations at R172 in these tumors, which has become a defining feature of this entity (4). We are presenting a case report of this rare entity in a 40-year-old female, currently named “Tall cell carcinoma with reverse polarity” by the World Health Organization (6) and there are only scattered case reports and very few case series published in the world literature to the best of our knowledge.

CASE REPORT

A 40-year-old female presented with pain and a palpable lump in the right breast for the past one month. Past history and family history were not significant. Mammography revealed a BIRADS IV lesion in the upper outer quadrant. Fine needle aspiration cytology was reported as proliferative breast disease with atypia, and trucut biopsy was inconclusive for malignancy. Hence patient underwent lumpectomy, which was followed later by modified radical mastectomy with axillary clearance. The nodular lesion excised was relatively circumscribed, grey-white to yellow in color, firm in consistency, and measuring 5.5x4.5x4cm. The resection margin was formed by the lesion. Grossly, no areas of necrosis/hemorrhage were identified. Microscopy showed a tumor composed of nodules of neoplastic cells arranged in nests and solid papillary patterns with thin fibrovascular cores. Papillae were lined by tall columnar epithelial cells, having a moderate amount of granular eosinophilic cytoplasm, oval nuclei with moderate nuclear pleomorphism, nuclear overlapping, crowding, nuclear grooves, optical clearing of chromatin, and occasional intranuclear pseudo-inclusions. The linear arrangement of nuclei situated away from the basement membrane, so-called reverse polarity, was also seen at places. Foci with fibrovascular cores having clusters of foamy macrophages...
and follicular structures with colloid-like eosinophilic secretion were also noted. Mitosis was sparse (1-2 per 10 high power field). No necrosis, lymphovascular emboli, or perineural invasion were noted (Figure 1A-F).

Immunohistochemistry was performed using an automated stainer (Ventana Benchmark XT system*) with UltraView Universal DAB detection. The antibodies used were GATA3, GCDFP-15, estrogen receptor (ER), progesterone receptor (PgR), Androgen receptor (AR), HER2/neu, synaptophysin, chromogranin A, Bcl2, EMA, CK 5/6, p63, thyroid transcription factor 1 (TTF-1), inhibin, and Ki67. Antibody details are shown in Table I. The neoplastic cells were immuno-positive for GATA3, CK5/6, EMA and calretinin with patchy and weak expression for ER and PgR. AR showed heterogenous staining pattern with peripheral accentuation in the tumor lobules (Figure 2A-I), which has

---

**Figure 1:** Histomorphological features of Tall cell carcinoma with reverse polarity (TCCRP).  
A) Tumor composed of compact solid nests in a background of fibrotic stroma, (H&E; x40).  
B) Nest and papillae are lined by tall columnar epithelial cells, nuclei exhibiting reverse polarity (arrow) (H&E; x100).  
C) Tumor cells have eosinophilic granular cytoplasm, oval nuclei with chromatin clearing, and intranuclear pseudo-inclusion (Inset show intranuclear pseudo inclusion) (H&E; x100).  
D) Nuclei exhibit crowding, overlapping and nuclear groove (Inset show nuclear groove) (H&E; x400).  
E) Follicular structures with eosinophilic/amphophilic colloid-like secretions (H&E; x100).  
F) Fibrovascular core with foamy macrophages (H&E x100).
not been described earlier in the literature. While neoplastic cells were immuno-negative for HER2/neu, synaptophysin, chromogranin, Bcl2, GCDFP-15, TTF1, and inhibin, the Ki67 proliferation index was 5%. No staining for p63 was seen around the lobules. Immunohistochemical features of the tumors are illustrated in Figure 2.

DNA was isolated from formalin-fixed paraffin-embedded blocks and targeted sequencing for the commonly mutated site of IDH1 (R132) and IDH2 (R172) was performed through a bi-directional Sanger sequencing method on the amplified template. The tumor tissue showed a mutation in the IDH2 gene (DNA description: c.A514>G; Protein description: p.Arg172Gly – R172G). DNA sequence chromatogram for the IDH2 gene is shown in Figure 3. Based on the characteristic immuno-morphology and molecular findings, a diagnosis of tall cell carcinoma with reverse polarity was made. Following lumpectomy, completion mastectomy with axillary lymph node dissection was performed owing to the positive surgical margin. Grossly and microscopically, no residual tumor was identified and all nine axillary lymph nodes were free of tumor. PET-CT scan revealed no evidence of metastasis. No further treatment was given owing to the indolent behavior of the tumor, and the patient is under observation and is currently disease-free for 6 months post-surgery. Written informed consent for publication was taken from the patient.

### DISCUSSION

Tall cell carcinoma with reverse polarity is a recently described invasive breast carcinoma, included in the 5th edition of WHO classification of breast tumors as a slow-growing tumor with favorable prognosis (1-6). These tumors most commonly occur in women around the age of 65 years (range 52 to 75 years), with characteristic immuno-morphologic features. Molecular studies have shown IDH2 mutation in almost all of these tumors, which has become a defining feature. Morphologically, they form well-circumscribed masses with cells arranged in compact solid nests in a background of fibrotic stroma, having thin fibrovascular cores that recapitulates a solid-papillary pattern, and sometimes the cores contain foamy macrophages. Papillae are lined by tall columnar cells having abundant eosinophilic cytoplasm, bland oval to round nuclei exhibiting nuclear grooves and intranuclear psammoma bodies, granular calcification, and follicular structures with eosinophilic/amphophilic colloid-like secretions are sometimes noted (7). Areas of necrosis, lymphovascular emboli, or peri-neural invasions are usually not seen (8). The present case showed all the

### Table I: Details of primary antibodies.

<table>
<thead>
<tr>
<th>Anti-sera</th>
<th>Source</th>
<th>Clone</th>
<th>Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>AR</td>
<td>BioGenex</td>
<td>F39.4.1</td>
<td>1:20</td>
</tr>
<tr>
<td>Bcl-2</td>
<td>Bio SB</td>
<td>BSB-5</td>
<td>1:200</td>
</tr>
<tr>
<td>Calretinin</td>
<td>BioGenex</td>
<td>2E7</td>
<td>1:30</td>
</tr>
<tr>
<td>CK5/6</td>
<td>Bio SB</td>
<td>B5-16B4</td>
<td>1:150</td>
</tr>
<tr>
<td>Chromogranin</td>
<td>Bio SB</td>
<td>LK2H10</td>
<td>1:4000</td>
</tr>
<tr>
<td>EMA</td>
<td>BioGenex</td>
<td>E29</td>
<td>1:120</td>
</tr>
<tr>
<td>ER</td>
<td>Roche</td>
<td>SP1</td>
<td>Pre-diluted</td>
</tr>
<tr>
<td>GATA3</td>
<td>Bio SB</td>
<td>L50-823</td>
<td>1:100</td>
</tr>
<tr>
<td>GCDFP-15</td>
<td>BioGenex</td>
<td>EP95</td>
<td>1:50</td>
</tr>
<tr>
<td>HER 2</td>
<td>Roche</td>
<td>4B5</td>
<td>Pre-diluted</td>
</tr>
<tr>
<td>Inhibin</td>
<td>BioGenex</td>
<td>R1</td>
<td>1:30</td>
</tr>
<tr>
<td>Ki67</td>
<td>BioGenex</td>
<td>MIB-1</td>
<td>1:50</td>
</tr>
<tr>
<td>PgR</td>
<td>Roche</td>
<td>1E2</td>
<td>Pre-diluted</td>
</tr>
<tr>
<td>P63</td>
<td>BioGenex</td>
<td>4A4</td>
<td>1:50</td>
</tr>
<tr>
<td>Synaptophysin</td>
<td>BioGenex</td>
<td>SMP 88</td>
<td>1:150</td>
</tr>
<tr>
<td>TTF-1</td>
<td>BioGenex</td>
<td>SP141</td>
<td>1:80</td>
</tr>
</tbody>
</table>

Figure 2: A) Neoplastic cells show weak and patchy expression for ER (IHC; x100) and B) PgR (IHC; x400). C) AR showed heterogenous staining pattern with intense staining at the peripheral of the tumor (IHC; x100). D) Neoplastic cells are positive for CK5/6 (IHC; x40), E) Calretinin (IHC; x40), F) GATA-3 (IHC; x40), G) with luminal expression of EMA (IHC; x400). H) Low Ki67 proliferation (IHC; x100) and I) negative for TTF-1 (IHC; x40).

Figure 3: DNA sequence chromatogram showing mutation in IDH2 gene at R172.
above characteristic morphological features. These tumors show weak or absent ER, PgR, AR expression, and are almost always negative for HER2/neu. Although morphological features of TCCRP resemble papillary thyroid carcinoma, they are negative for TTF-1, thyroglobulin and HBME 1, and the breast origin of the neoplasm is confirmed by the positive staining for markers of mammary differentiation like GATA3, mammaglobin and GCDFP-15. Myoepithelial markers p63, SMMHC, and calponin are absent within and around the lesion, suggestive of invasive disease. Neoplastic cells are also immunopositive for CK5/6, and focally for EMA, CEA, and bcl-2, and exhibit a low Ki67 proliferation index ranging from 1 to 5%. All TCCRP also show diffuse and strong expression of calretinin. The immunohistochemical profile in the present case was similar to the cases described in the literature, with strong expression of GATA3, CK5/6, calretinin, and weak expression of hormone receptors, and AR showed a heterogenous staining pattern with peripheral accentuation in the tumor lobules (Figure 2C), which has not been described earlier in the literature. Ki67 proliferation was low (5%). In addition, the neoplastic cells showed patchy expression of GCDFP15 and luminal expression of EMA.

In conclusion, TCCRP is a rare and newly described entity with characteristic morphological features that can mimic other papillary lesions of the breast. IDH2 hotspot mutation is a distinctive and characteristic finding in TCCRP. A high index of suspicion is necessary to avoid misdiagnosis of TCCRP as other papillary breast lesions or metastasis from the thyroid, and accurate diagnosis of this entity is necessary as it carries an excellent prognosis.

CONFLICT of INTEREST

None of the authors have any competing interests.

FUNDING

None

ACKNOWLEDGEMENTS

We thank Dr Vani Santosh, Professor of Neuropathology, Department of Neuropathology, NIMHANS, Bengaluru, for carrying out molecular analysis for IDH2 mutation.

AUTHORSHIP CONTRIBUTIONS


REFERENCES


